(19)
(11) EP 0 811 060 A1

(12)

(43) Date of publication:
10.12.1997 Bulletin 1997/50

(21) Application number: 96902265.0

(22) Date of filing: 12.02.1996
(51) International Patent Classification (IPC): 
C12N 15/ 09( . )
A61K 48/ 00( . )
A61P 37/ 04( . )
C12N 15/ 00( . )
C12P 21/ 02( . )
C12R 1/ 92( . )
 A61K 38/ 00( . )
A61P 31/ 12( . )
C07K 14/ 47( . )
C12N 15/ 12( . )
C12R 1/ 91( . )
(86) International application number:
PCT/EP1996/000585
(87) International publication number:
WO 1996/025492 (22.08.1996 Gazette 1996/38)
(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
Designated Extension States:
SI

(30) Priority: 13.02.1995 GB 19950002771
03.07.1995 GB 19950013505

(71) Applicants:
  • Novartis AG
    4058 Basel (CH)
  • Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
    1230 Wien (AT)

(72) Inventor:
  • HAUBER, Joachim
    D-91054 Erlangen (DE)

(74) Representative: Roth, Bernhard M. 
Novartis AG Geistiges Eigentum Konzern
4002 Basel
4002 Basel (CH)

   


(54) EUKARYOTIC INITIATION FACTOR 5A (eIF-5A) MUTANTS